The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
You seem to misunderstand the purpose of finding a MTD. It has no relevance to determination of concentrations of dox in TME.
Determining MTD is essential in designing dosing regimes. Duration of dosing influences MTD because individuals may be less able to tolerate consecutive high doses over long periods of time. MTD for a single administration may be different than the MTD for three or more days of dosing which may be different for MTD for seven days dosing or 28 days dosing etc etc etc
Defining the MTD in a study informs dose setting for all future studies/tumor types etc etc. It is that simple!
……. But is helpful to some to try and convince others that MTD actually relates to TME dox concentration. MTD relates to one thing only and that is TOLERABILITY (the clue is in the name).
It was just over 5 weeks ago they announced a minimum $US35m win. That win was about 10% of the future order book.
Historically they win around 3-5 auto wins a year. They aren’t going to win a contract every 6 weeks!
Yes that could be a scenario.
Would have thought an outfit of that calibre would be more interested in taking a 15% stake at a low MCAP for a revolutionary cancer treatment……. having seen how good the data was.
I guess we won’t know until there is potential for a tr1 later this year.
“ I also think it’s the bond being sold. As I said yesterday, they’d make a quick million or so. Who knows what there approach is. ”
The destroys the narrative that to loan the 60 odd million they must have had sight of the data etc etc. If they had sight of the data then surely they would hold their shares at 118p.
IMO there is obviously a fair few short on Avacta (winteeth etc) and this is their push to reduce loss pre science day.
This stock desperately needs a stronger II holding.
Snuppet,
Look at the investor videos the company has put out over the past year. Nothing “timid” about those.
The company has provided plenty of PR since June 2022 and their claim of 50% market share.
It is clear AVA6000 can deliver a therapeutically MEANINGFUL dose of doxorubicin into the tumour tissue while when we measure the concentration in the blood stream at exactly the same time the concentration is very much lower.”
Chutz,
Don’t apologise for posting. Your thoughts align with mine and I suspect many others invested in SEE.
The presentation from October shows when the high margin current booked business comes to fruition and the hockey stick is just at the beginning of the curve upwards in 2023.
I have complete faith in how management is performing and the direction they are taking the company.
They have near enough stated it. The degree of reduction in side effects will be revealed on science day.
“AVA6000 continues to be well tolerated by patients in cohort 4 with a marked reduction in the incidence and severity of the typical toxicities associated with the standard doxorubicin chemotherapy administration.”
It doesn't necessarily mean there were 7 withdrawals. The 3x3 dose escalation means that if there are any toxic response in the first 3 patients recruited then another 3 need to be recruited into that cohort and a total of only 1 toxic response from the 6 patients is allowed for that cohort to progress to the next dosing level. This has obviously happened in a couple of the cohorts otherwise the timelines for each cohort would be similar to cohort 3.
CES is about new products and announcing partnerships. The company has never released a won contract at CES so I wasn’t expecting anything in that regard but am extremely hopefully that we will see big contracts coming in over the next quarter. The partnerships they have put in place put them in a great position to hit their 50% market share target.
Secondary endpoints like ORR and others use the Response Evaluation Criteria in Solid Tumors (RECIST 1.1) protocol which measures the size of tumor’s amount other things so this data is definitely being collected.
“ Just have a loo at what Magna is paying for Veoneer and the order book for the company, which is in excess of $1B so if we get £1 per share at an order book of $1B that is really paying top dollar.”
This is really irrelevant though isn’t it. What is the profit margin Veoneer is making on that $billion dollar order book? Basing a valuation of SEE’s technology and order book based on Magna’s purchase of Veoneer needs to take into consideration many other things than just a comparison of the order book and the value paid for the company. From what I have read Veoneer’s margin on that order book is not even closely comparable to the DMS royalty margins SEE will receive.
SEE still has to win as much of the latest RFQ that it can inorder to get the billion dollar plus order book. All will become clearer in the next 12 months in that regard, but what is certain is the high margin dms auto royalties are not yet significantly shown on SEE’s accounts, but they will be soon enough…….and the market will then wake up.